Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian cancer: Expression and clinicopathological correlations. | Gynecol Oncol | 2026 | 42447657 | PubTator, text mining | PubMed |
| Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. | J Clin Oncol | 2026 | 42441925 | PubTator, text mining | PubMed |
| A narrative review of new strategies for immunotherapy combination treatment in platinum-resistant ovarian cancer: mechanisms, clinical evidence, and future directions. | Front Oncol | 2026 | 42441043 | PubTator, text mining | PubMed |
| ROS-Activatable "off-on" Fluorescent Prodrug Loaded Micelles for Targeted Therapy and in Situ Imaging of Breast Cancer Cells. | Int J Pharm X | 2026 | 42436868 | PubTator, text mining | PubMed |
| FRα expression in borderline ovarian tumors and low-grade serous ovarian carcinoma: prognostic and immune microenvironmental associations. | J Ovarian Res | 2026 | 42432725 | PubTator, text mining | PubMed |
| Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors. | Cancer Res Commun | 2026 | 42378456 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in gynecologic malignancies: breakthroughs, challenges, and future directions. | Front Immunol | 2026 | 42375351 | PubTator, text mining | PubMed |
| Toward molecular and pathology-confirmed completeness in advanced ovarian cancer cytoreduction: Intraoperative molecular imaging and integrated theranostic strategies. | Mol Aspects Med | 2026 | 42364525 | PubTator, text mining | PubMed |
| Folate Receptor Alpha Autoantibodies in Early Pregnancy: First-Trimester Reference Intervals and Proposed Clinical Thresholds. | Methods Protoc | 2026 | 42347032 | PubTator, text mining | PubMed |
| Folate Receptor Alpha Autoantibodies in Vector-Borne Disease Populations. | Diseases | 2026 | 42346294 | PubTator, text mining | PubMed |
| Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer. | Curr Oncol | 2026 | 42346230 | PubTator, text mining | PubMed |
| FOLR1-targeted actinium-225-based alpha-particle therapy eliminates ovarian cancer. | Sci Adv | 2026 | 42341116 | PubTator, text mining | PubMed |
| Folate receptor-α targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies. | Int Immunopharmacol | 2026 | 42322854 | PubTator, text mining | PubMed |
| Advances in immunotherapies in ovarian cancer. | J Immunother Cancer | 2026 | 42320989 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in gynaecological cancers: opportunities and challenges. | Nat Rev Clin Oncol | 2026 | 42310472 | PubTator, text mining | PubMed |
| Excess folic acid disrupts placental endocrine function in vitro: a potential mechanism linking elevated folic acid exposure with gestational diabetes mellitus. | Front Nutr | 2026 | 42293194 | PubTator, text mining | PubMed |
| Mirvetuximab soravtansine in platinum-resistant ovarian cancer: from biological rationale to clinical impact and future directions. | Int J Clin Oncol | 2026 | 42287581 | PubTator, text mining | PubMed |
| Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials. | Cancer Innov | 2026 | 42266555 | PubTator, text mining | PubMed |
| High folate receptor expression is associated with aggressive features in prostate cancer with low prostate-specific membrane antigen expression. | BJUI Compass | 2026 | 42255325 | PubTator, text mining | PubMed |
| Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia. | Blood Neoplasia | 2026 | 42255261 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=3